Sensei director granted options on 12,500 shares

Sensei Biotherapeutics director Phillip B. Donenberg received a stock option grant covering 12,500 shares of common stock.

Rhea-AI Filing Summary

Sensei Biotherapeutics director Phillip B. Donenberg received a stock option grant covering 12,500 shares of common stock. The option has an exercise price of $11.41 per share and expires on June 9, 2036.

The award vests in 12 equal monthly installments over one year, so it becomes fully vested on June 10, 2027, as long as Donenberg continues to provide service to the company on each vesting date. After this grant, he holds options for 12,500 shares directly.

Insider Trade Summary

Grant/Award: 12,500 shares

Grant/Award 1 txn

Insider Donenberg Phillip B.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	12,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 12,500 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on June 10, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Key Figures

Option grant size: 12,500 shares Exercise price: $11.41/share Expiration date: June 9, 2036 +2 more

5 metrics

Option grant size 12,500 shares Underlying common stock for new stock option award

Exercise price $11.41/share Stock option strike price

Expiration date June 9, 2036 Option term end date

Vesting schedule length 12 months Monthly vesting until fully vested June 10, 2027

Post‑grant option holdings 12,500 options Total derivative securities held directly after transaction

Key Terms

Stock Option (right to buy), exercise price, vesting, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 11.4100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to the option vest and become exercisable in 12 equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-06-09T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Sensei Biotherapeutics (SNSE) director Phillip Donenberg report on this Form 4?

Phillip B. Donenberg reported receiving a stock option grant for 12,500 shares of Sensei Biotherapeutics common stock. The option was awarded as compensation, rather than bought in the open market, and gives him the right to purchase shares at a set price in the future.

What are the key terms of the SNSE stock options granted to Phillip Donenberg?

The stock option covers 12,500 underlying shares with an exercise price of $11.41 per share and an expiration date of June 9, 2036. These terms define how many shares he can buy, at what price, and for how long the option remains exercisable.

How do the SNSE options granted to Phillip Donenberg vest over time?

The options vest in 12 equal monthly installments over one year, becoming fully vested on June 10, 2027. Each monthly vesting requires Donenberg to remain in continuous service with Sensei Biotherapeutics, aligning the award with ongoing board or service commitments.

How many Sensei Biotherapeutics derivative securities does Phillip Donenberg hold after this grant?

After the transaction, Donenberg holds stock options for 12,500 underlying shares directly. This Form 4 shows only this option position, indicating his reported derivative holdings now match the size of the newly granted award at the disclosed terms.

Is Phillip Donenberg buying or selling SNSE shares in this Form 4 filing?

He is not buying or selling shares on the open market. Instead, he received a compensatory stock option grant, classified as an acquisition under code “A.” The option gives future purchase rights rather than reflecting an immediate stock trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 08:35 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donenberg Phillip B.

(Last) (First) (Middle)

C/O SENSEI BIOTHERAPEUTICS, INC.

1405 RESEARCH BLVD, SUITE 125

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sensei Biotherapeutics, Inc. [ SNSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$11.41	06/10/2026		A(1)		12,500		(1)	06/09/2036	Common Stock	12,500	$0	12,500	D

Explanation of Responses:

1. The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on June 10, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Josiah Craver, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)